Cargando…
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836109/ http://dx.doi.org/10.2337/dc13-er12a |
| _version_ | 1782292268163530752 |
|---|---|
| author | Schernthaner, G Gross, JL Rosenstock, J Guarisco, M Fu, M Yee, J Kawaguchi, M Canovatchel, W Meininger, G |
| author_facet | Schernthaner, G Gross, JL Rosenstock, J Guarisco, M Fu, M Yee, J Kawaguchi, M Canovatchel, W Meininger, G |
| author_sort | Schernthaner, G |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3836109 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-38361092014-10-01 Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 Schernthaner, G Gross, JL Rosenstock, J Guarisco, M Fu, M Yee, J Kawaguchi, M Canovatchel, W Meininger, G Diabetes Care Errata American Diabetes Association 2013-12 2013-11-13 /pmc/articles/PMC3836109/ http://dx.doi.org/10.2337/dc13-er12a Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
| spellingShingle | Errata Schernthaner, G Gross, JL Rosenstock, J Guarisco, M Fu, M Yee, J Kawaguchi, M Canovatchel, W Meininger, G Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 |
| title | Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 |
| title_full | Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 |
| title_fullStr | Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 |
| title_full_unstemmed | Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 |
| title_short | Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 |
| title_sort | canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. diabetes care 2013;36:2508–2515 |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836109/ http://dx.doi.org/10.2337/dc13-er12a |
| work_keys_str_mv | AT schernthanerg canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT grossjl canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT rosenstockj canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT guariscom canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT fum canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT yeej canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT kawaguchim canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT canovatchelw canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 AT meiningerg canagliflozincomparedwithsitagliptinforpatientswithtype2diabeteswhodonothaveadequateglycemiccontrolwithmetforminplussulfonylureaa52weekrandomizedtrialdiabetescare20133625082515 |